STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Feb. 29, 2016	Feb. 28, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (2,005,100)	$ (2,892,048)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	684	684
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph. D.	1,790,386	2,548,598
Changes in operating assets and liabilities
Accounts payable	(35,500)	(14,427)
Accrued liabilities	(1,486)	3,515
NET CASH USED IN OPERATING ACTIVITIES	(251,016)	(353,678)
CASH FLOWS FROM FINANCING ACTIVITIES
Cash contribution recorded	252,039	355,729
NET CASH PROVIDED BY FINANCING ACTIVITIES	252,039	355,729
NET INCREASE IN CASH	1,023	2,051
CASH AT BEGINNING OF YEAR	2,280	229
CASH AT END OF YEAR	$ 3,303	$ 2,280